logo

For the Inventor, By the Inventor

Kalamazoo, MI, United States of America

Martin Durham Meglasson

This inventor holds 18 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Pharmacia & Upjohn Company, The Upjohn Co., Pharmacia Corporation. Active years: 1992-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin Durham Meglasson. Retrieved from https://idiyas.com/inventor/martin-durham-meglasson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18

% Patents Active = 77.8

Average Co-Inventor Count = 1.9

ph-index = 5

Forward Citations = 76(Granted Patents)


Company Filing History:

goldMedal11 out of 523 
 
Pharmacia & Upjohn Company
 patents
silverMedal4 out of 2,170 
 
The Upjohn Co.
 patents
bronzeMedal1 out of 220 
 
Pharmacia Corporation
 patents
4. 2 out of 834,601 
Other
 patents

Years Active: 1992-2005

Loading Chart...
Areas of Expertise:
Quaternary Ammonium Compounds
Aminoguanidine Carboxylates
Non-Insulin-Dependent Diabetes
Obesity Treatment
Endurance Enhancement
3-Guanidinopropionic Acid
Sexual Disturbances
Carboxylate Lactams
Food Products
Adiposity Treatment
18 patents (USPTO):Explore Patents
1. 6951950 - Quaternary ammonium compounds (2005-10-04),
2. 6921771 - Method of treating sexual disturbances (2005-07-26),
3. 6903127 - Method of treating sexual disturbances (2005-06-07),
4. 6890945 - Method of treating sexual disturbances (2005-05-10),
5. 6809112 - Method of treating sexual disturbances (2004-10-26),
6. 6455564 - Method of treating sexual disturbances (2002-09-24),
7. 6329545 - Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus (2001-12-11),
8. 6274580 - Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus (2001-08-14),
9. 6184216 - Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus (2001-02-06),
10. 6177453 - Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus (2001-01-23),
11. 6166080 - Aminoquanidine carboxylates for the treatment of obesity (2000-12-26),
12. 6008253 - Use of 3-guanidinopropionic acid to increase endurance, stamina and (1999-12-28),
13. 5994577 - Aminoguanidine carboxylates for the treatment of non-insulin-dependent (1999-11-30),
14. 5955617 - Aminoguanidine carboxylate lactams for the treatment of (1999-09-21),
15. 5900435 - Composition, food product and uses of 3-guanidinopropionic acid (1999-05-04),

Title: Martin Durham Meglasson: Innovator in Pharmaceutical Compounds

Introduction

Martin Durham Meglasson is a notable inventor based in Kalamazoo, MI (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 18 patents. His work primarily focuses on innovative treatments for various medical conditions.

Latest Patents

Among his latest patents, Meglasson has developed quaternary ammonium compounds that are effective in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis. Additionally, he has created a method for treating sexual disturbances in humans and inducing mating in non-human mammals, utilizing specific compounds in precise dosage ranges.

Career Highlights

Throughout his career, Meglasson has worked with prominent companies such as Pharmacia & Upjohn Company and The Upjohn Company. His expertise in pharmaceutical innovations has led to advancements that benefit both human and animal health.

Collaborations

Some of his notable coworkers include Scott D Larsen and Valerie Ann Vaillancourt. Their collaborative efforts have contributed to the success of various projects and innovations in the pharmaceutical industry.

Conclusion

Martin Durham Meglasson stands out as a significant figure in the realm of pharmaceutical inventions, with a focus on improving health outcomes through innovative treatments. His contributions continue to impact the medical field positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…